Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The Center for Medicare & Medicaid Services will award four states a three-year contract to support the implementation of text4baby, a free mobile health service for expecting and new moms.
The majority of patients report positive feelings after viewing their laboratory results online, according to a Kaiser Permanente study published in the Journal of Participatory Medicine.
The National Institutes of Health’s (NIH) Center for Advancing Translational Sciences awarded $18 million to Dartmouth College in Hanover, N.H., to advance translational medicine.
As the federal government shutdown continues with nearly 70 percent of Centers for Disease Control & Prevention (CDC) employees furloughed, athenaResearch will help fill the gap by sharing its data on communicable diseases, starting with the flu.
This week, we partnered with AMDIS and Elsevier to present the first AMDIS Fall Symposium which covered challenges and opportunities for health information exchange, EHRs, care coordination, the changing physician-patient relationship and more.
E-prescribing has shown remarkable gains since 2008, according to a study conducted by the Office of the National Coordinator for Health IT and published in the American Journal of Managed Care.
Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.
RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.
